Curetech Ltd. today announced the final successful results of its Phase II clinical trial of CT-011 stem cell treatment of Diffuse Large B Cell Lymphoma. The trial achieved it primary endpoint of improved progression-free survival, and its secondary endpoint of overall survival.
The trial included 72 patients with aggressive lymphoma at 30 centers in the US, Asia, South America and Israel. In the final results, 71% of the patients had no progression in the disease at the end of the follow-up period, compared with 58% in the historical control. 83% of patients were alive at the end of the follow-up period, compared with 66% in the historical control. CT-011 also increased the number of immune cells for creating an immune response memory, which enables long-term protection against lymphoma.
IDB Holding Corp. Ltd. (TASE:IDBH) venture capital arm Clal Biotechnology Industries Ltd. (TASE: CBI) owns 37% of Curetech and Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) owns 33%, and it has an option to increase the stake.
CBI's share price jumped 5.5% on the news, but fell back to a gain of 2.2% by midday to NIS 15.69, giving a market cap of NIS 1.56 billion. Teva's share price fell 1.4% to NIS 146, after rising 2.5% on Nasdaq yesterday to $40.33, giving a market cap of $37.9 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on September 8, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011